Immune cell therapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental cell therapy using immune cells called iNKT cells, which are designed to attack pancreatic cancer. It may be an option for people who have already tried standard treatments and are looking for something new.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that has spread or cannot be removed with surgery, and standard treatments have failed, caused severe side effects, or are not suitable for you.
- You have at least one tumor that can be measured on a scan (like CT or MRI).
- You are generally healthy enough to carry out daily activities on your own (ECOG score 0-1).
- You expect to live at least 3 more months.
- You have had no serious heart problems, brain metastasis, or active infections in the recent past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new treatment using specially engineered immune cells (CAR macrophages) that are designed to find and attack a protein called c-MET on pancreatic cancer cells. It may help people whose cancer has not responded to previous treatments or who could not tolerate them.
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.